Hemispherx BioPharma, Inc Share Price Nyse
Equities
US42366C3016
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 2.57M 205M | Capitalization | 21.37M 1.71B |
---|---|---|---|---|---|
Net income 2024 * | -27M -2.16B | Net income 2025 * | -28M -2.24B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 8.31 x |
P/E ratio 2024 * |
-0.79
x | P/E ratio 2025 * |
-0.91
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.01% |
Latest transcript on Hemispherx BioPharma, Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 16/11/08 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 03/04/22 |
Chief Tech/Sci/R&D Officer | - | 31/05/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 27/03/23 |
William Mitchell
CHM | Chairman | 89 | 30/06/98 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 16/11/08 |
1st Jan change | Capi. | |
---|---|---|
-2.06% | 103B | |
+1.87% | 95.28B | |
+2.82% | 22.15B | |
-15.88% | 21.02B | |
-8.45% | 18.15B | |
-41.01% | 16.73B | |
-15.13% | 16.05B | |
+4.23% | 13.68B | |
+32.22% | 12.17B |